Navigation Links
Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs
Date:4/30/2008

BOSTON, April 30 /PRNewswire-FirstCall/ -- Today John C. Lechleiter, Ph.D., president and CEO of Eli Lilly and Company (NYSE: LLY), praised the Bay State for its investment in biotechnology and provided insight into the future of life sciences and a roadmap for ensuring the state's significant investment is rewarded. He made his remarks to the Massachusetts Biz/Bio Conference, a gathering of policymakers, business leaders and academics, under the theme "Economic Prosperity through Scientific Discovery." Massachusetts workers have enjoyed a 10 percent rise in the number of biopharmaceutical jobs, according to reports from Northeastern University, which contrasts favorably against the 25 percent decline in overall manufacturing jobs in the first half of the decade.

"This state really stands out for the approach that you've taken to developing the life-sciences sector - a sector in 'a Golden Age of discovery,'" said Lechleiter. He continued: "In Massachusetts, your legislature is about to make a dramatic, $1 billion public investment in the life sciences - through tax incentives, grants, and capital projects. That gives you an even larger stake in protecting the ability of biotech businesses to succeed, which is the basis of our ability to create jobs."

Lechleiter measured the region's commitment to biotechnology in several ways while noting that ongoing public policy debates would determine how well the region's investment could pay off. For example, he said Greater Boston ranks second only to San Diego in the Milken Institute's ranking of life-sciences clusters, and he tallied the economic impact of the biotechnology and pharmaceutical industries on the state at more than $5 billion a year.

These investments, he remarke
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (PRWEB) February 26, 2015 On Wednesday, ... to building a nationwide Clostridium difficile (C. diff) awareness ... diff burden study by the Centers for Disease Control ... caused almost half a million infections among Americans in ... nursing homes. , The study also estimates that ...
(Date:2/26/2015)... 26, 2015 Phosphate Therapeutics, ... the first pivotal trial of PT20 in subjects ... disease (DD-CKD), has completed as the pre-specified number ... invented by leading UK-based scientists from the Medical ... is a novel phosphate binder that is based ...
(Date:2/25/2015)... , Feb. 25, 2015 truBrain ... is featured in this week,s Power Pitch segment ... to discuss the company,s traction and growth strategy, ... the crowd funding site CircleUp. The ... that are validated by neurotechnology, while also discussing ...
(Date:2/25/2015)... HONG KONG, Feb. 25, 2015 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... fiscal 2015 ended December 31, 2014. Third ... the third quarter of fiscal 2015 increased by 10.7% ...
Breaking Biology Technology:Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 3China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 4China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 5China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 6China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 7China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 8China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 9China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 10China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 11China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 12China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 13China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 14China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 15China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 16China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 17China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 18China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 19China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 20China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 21China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 22
... Oct. 19 Americord Registry announced its breakthrough placenta ... new and significantly more effective alternative to private cord blood stem ... up to ten times more stem cells from the placenta than ... contains only enough stem cells to treat a patient weighing less ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
... I2BF Consolidates Position as a Global Leader in Cleantech Investment with New... -- NEW YORK, October 19, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Biology Technology:Americord Registry Becomes First Cord Blood Bank to Offer Placenta Preservation, Advancing Cord Blood Stem Cell Therapy Options 2SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 2SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 3SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 4SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 5SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 6SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 7SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 8SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 9I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 2I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 3I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 4I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 5I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 6I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 7I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 8I2BF Consolidates Position as a Global Leader in Cleantech Investment with New York Office Opening and Team Expansion 9
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , a ... will showcase its EyeLock ID technology integrated in a 3D ... Oak Ridge National Laboratory (ORNL) at the 2015 ... authentication technology is being used to validate the driver and ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... London) scientists have found that the closest living relative to ... The team tested for DNA and skeletal features to prove ... Siberia with prehistoric man and is the subject of numerous ... fallow deer, one of the most widespread deer in the ...
... to provide some protection to the heart from injury ... a heart attack, Jefferson Medical College researchers report. , ... Medicine in the Department of Medicine at Jefferson Medical ... co-workers knew that the drug Darbepoietin alpha would protect ...
... documented that illegal blood donation practices led to high hepatitis ... during the 1980s and early 1990s, and that failure to ... infection as well, according to an article in the November ... online. , Some blood donation facilities in rural China illegally ...
Cached Biology News:Extinct giant deer's descendant found in UK 2Past illegal blood donation in China linked to hepatitis C virus infection 2
...
...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Request Info...
Biology Products: